The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Ivabradine in Stable Coronary Artery Disease without Clinical Heart Failure
Open accessAbstract
BACKGROUND: An elevated heart rate is an established marker of cardiovascular risk. Previous analyses have suggested that ivabradine, a heart-rate-reducing agent, may improve outcomes in patients with stable coronary artery disease, left ventricular dysfunction, and a heart rate of 70 beats per minute or more. METHODS: We conducted a randomized, double-blind, placebo-controlled trial of ivabradine, added to standard background therapy, in 19,102 patients who had both stable coronary artery disease without clinical heart failure and a heart rate of 70 beats per minute or more (including 12,049 patients with activity-limiting angina [class ≥II on the Canadian Cardiovascular Society scale, which ranges from I to IV, with higher classes indicating greater limitations on physical activity owing to angina]). We randomly assigned patients to placebo or ivabradine, at a dose of up to 10 mg twice daily, with the dose adjusted to achieve a target heart rate of 55 to 60 beats per minute. The primary end point was a composite of death from cardiovascular causes or nonfatal myocardial infarction. RESULTS: At 3 months, the mean (±SD) heart rate of the patients was 60.7±9.0 beats per minute in the ivabradine group versus 70.6±10.1 beats per minute in the placebo group. After a median follow-up of 27.8 months, there was no significant difference between the ivabradine group and the placebo group in the incidence of the primary end point (6.8% and 6.4%, respectively; hazard ratio, 1.08; 95% confidence interval, 0.96 to 1.20; P=0.20), nor were there significant differences in the incidences of death from cardiovascular causes and nonfatal myocardial infarction. Ivabradine was associated with an increase in the incidence of the primary end point among patients with activity-limiting angina but not among those without activity-limiting angina (P=0.02 for interaction). The incidence of bradycardia was higher with ivabradine than with placebo (18.0% vs. 2.3%, P<0.001). CONCLUSIONS: Among patients who had stable coronary artery disease without clinical heart failure, the addition of ivabradine to standard background therapy to reduce the heart rate did not improve outcomes. (Funded by Servier; SIGNIFY Current Controlled Trials number, ISRCTN61576291.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For the indication of stable coronary disease, none of these medications have been shown to reduce the risk of mortality or myocardial infarction.”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [249]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study
Swedberg, K., Komajda, M., Böhm, M., Borer, J. S., Ford, I., Dubost-Brama, A., Lerebours, G., & Tavazzi, L. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61198-1 · Cited by 2,563
Self-citationGibbons, R. J., Abrams, J., Chatterjee, K., Daley, J., DEEDWANIA, P. C., Douglas, J. S., Ferguson, T. B., Fihn, S. D., Fraker, T. D., Gardin, J. M., et al. (2002) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(02)02848-6 · Cited by 1,685
Guidelines on the management of stable angina pectoris: executive summary
Authors/Task Force Members, Fox, K. M., Garcia, M. A. A., Ardissino, D., Buszman, P. E., Camici, P. G., Crea, F., Daly, C., Backer, G. D., Hjemdahl, P., et al. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehl001 · Cited by 1,332
Self-citationHeart rate and cardiovascular mortality: The Framingham study
Kannel, W. B., Kannel, C., Paffenbarger, R. S., & Cupples, L. A. (1987) · American Heart Journal · doi:10.1016/0002-8703(87)90666-1 · Cited by 1,292
Böhm, M., Swedberg, K. B., Michel Komajda, N., BORER, J. S., Ford, I., Dubost-Brama, A., Lerebours, G., & Tavazzi, L. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61259-7 · Cited by 1,100
Self-citationFox, K., Ford, I., Steg, P. G., Tendera, M., & Ferrari, R. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61170-8 · Cited by 1,099
Self-citationResting Heart Rate in Cardiovascular Disease
Fox, K., Borer, J. S., Camm, A. J., Danchin, N., Ferrari, R., Lopez Sendon, J. L., Steg, P. G., Tardif, J.-C., Tavazzi, L., & Tendera, M. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.04.079 · Cited by 1,062
Self-citationDiaz, A., Bourassa, M. G., Guertin, M.-C., & Tardif, J.-C. (2005) · European Heart Journal · doi:10.1093/eurheartj/ehi190 · Cited by 790
Self-citationFox, K., Ford, I., Steg, P. G., Tendera, M., Robertson, M., & Ferrari, R. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61171-x · Cited by 789
Self-citationTardif, J., Ford, I., Tendera, M., Bourassa, M. G., & Fox, K. M. (2005) · European Heart Journal · doi:10.1093/eurheartj/ehi586 · Cited by 580
Self-citation
Cited by
Sorted by citations
Items 301–400 of 485
Comments on the 2019 ESC guidelines on chronic coronary syndromes
Sambola, A., Ibáñez, B., Andrea, R., Berga, G., González, J. A. B., Delgado, V., Ferreiro, J. L., Navarro, F., Raposeiras‐Roubín, S., Lecoq, R. R., et al. (2020) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2019.12.023 · Cited by 4
Szabó, P. L., Marksteiner, J., Ebner, J., Dostal, C., Podesser, B. K., Sauer, J., Kubista, H., Todt, H., Hackl, B., Koenig, X., et al. (2023) · Physiological Reports · doi:10.14814/phy2.15664 · Cited by 4
Habal, M. V., Nanthakumar, K., Austin, P. C., Freitas, C., Labos, C., & Lee, D. S. (2018) · BMC Cardiovascular Disorders · doi:10.1186/s12872-018-0751-2 · Cited by 4
Tondi, L., Fragasso, G., Spoladore, R., Pinto, G., Gemma, M. F., Slavich, M., Godino, C., Salerno, A., Montanaro, C., & Margonato, A. (2018) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000000661 · Cited by 4
Bunin, Y. А., Miklishanskaya, S. V., Александровна, З. Е., & Васильевна, Ч. В. (2019) · Rational Pharmacotherapy in Cardiology · doi:10.20996/1819-6446-2019-15-1-115-124 · Cited by 4
Ivabradine and metoprolol in fixed dose combination: When, why and how to use it
Katsi, V., Skalis, G., Kallistratos, M. S., Tsioufis, K., Makris, T., Manolis, A. J., & Tousoulis, D. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104279 · Cited by 4
The Influence of Resting Heart Rate on Central Pulse Pressure is Age-Dependent
Alfie, J., Aparicio, L. S., & Cuffaro, P. E. (2021) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-020-00432-8 · Cited by 4
Adaptation of Arterial Wall Viscosity to the Short‐Term Reduction of Heart Rate: Impact of Aging
Roca, F., Iacob, M., Duflot, T., Donnadieu, N., Thill, C., Bellien, J., & Joannidès, R. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.121.023409 · Cited by 4
Chin, J., Fulcher, J., Jenkins, A. J., & KEECH, A. C. (2014) · Heart Lung and Circulation · doi:10.1016/j.hlc.2014.11.016 · Cited by 4
Wu, W., Zhang, L., Zhao, J., Guo, Y., Liu, J., Shi, D., Yang, J., Liu, Y., Lai, J., & Shen, Z. (2019) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2019.7531 · Cited by 4
Estep, J. D. (2015) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000186 · Cited by 4
Refractory angina: new drugs on the block
Giannopoulos, A. A., Giannoglou, G. D., & Chatzizisis, Y. S. (2016) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2016.1198695 · Cited by 4
Kim, Y., Ahn, M., Yoo, B., Kim, J., Son, J., Park, Y. J., Kim, S. H., Kang, D. R., Lee, H., Kang, S., et al. (2024) · International Journal of Heart Failure · doi:10.36628/ijhf.2023.0052 · Cited by 3
Pagel, P. S., Hang, D., Freed, J. K., & Crystal, G. J. (2025) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2025.03.029 · Cited by 3
Progress in the Presence of Failure: Updates in Chronic Systolic Heart Failure Management
Murphy, K. M., & Rosenthal, J. (2017) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-017-0552-4 · Cited by 3
A Literature Review of Genetic Markers Conferring Impaired Response to Cardiovascular Drugs
Shukla, H. J., Mason, J. L., & Sabyah, A. (2018) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-018-0267-2 · Cited by 3
Bhatt, P. A., Bhavsar, N., Naik, D. K., & Shah, D. A. (2021) · Indian Journal of Pharmacology · doi:10.4103/ijp.ijp_478_19 · Cited by 3
Izumida, T., Imamura, T., Onoda, H., Tanaka, S., Ushijima, R., Ueno, H., & Kinugawa, K. (2024) · International Heart Journal · doi:10.1536/ihj.24-027 · Cited by 3
Nationale Versorgungsleitlinie (NVL) Chronische KHK
Werdan, K. (2016) · CME · doi:10.1007/s11298-016-5747-6 · Cited by 3
Decreasing heart rate in heart failure
Natale, E., & Marsocci, A. (2018) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000000564 · Cited by 3
Advances in small-molecule therapy for managing angina pectoris in the elderly
Waheed, N., Mahmoud, A., Rambarat, C. A., & Pepine, C. J. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1615881 · Cited by 3
A Review of the Key Clinical Trials of 2014
McKavanagh, P., McCune, C., & Menown, I. B. A. (2015) · Cardiology and Therapy · doi:10.1007/s40119-015-0036-0 · Cited by 3
Ivabradine, Coronary Heart Disease, and Heart Failure: Time for Reappraisal
Štulc, T., & Češka, R. (2014) · Current Atherosclerosis Reports · doi:10.1007/s11883-014-0463-8 · Cited by 3
Ivabradine, a novel medication for treatment of heart failure with reduced ejection fraction
Foster, J. L., & Bobadilla, R. V. (2016) · Journal of the American Association of Nurse Practitioners · doi:10.1002/2327-6924.12371 · Cited by 3
Kosmidou, I., Crowley, A., Macedo, L., Ben‐Yehuda, O., Gersh, B. J., Boonstra, P. W., Kappetein, A. P., Serruys, P. W. J. C., Sabik, J. F., & Stone, G. W. (2019) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2019.10.004 · Cited by 3
Pathophysiology of Atrial Fibrillation
Burashnikov, A., & Antzelevitch, C. N. (2017) · Cardiovascular medicine · doi:10.1007/978-3-319-58000-5_2 · Cited by 3
Ferrari, R. (2015) · European Heart Journal Supplements · doi:10.1093/eurheartj/suv056 · Cited by 3
Self-citationSYK protects cardiocytes against anoxia and hypoglycemia-induced injury in ischemic heart failure
Yin, G., Yang, X., Li, Q., & Guo, Z. (2017) · Molecular Immunology · doi:10.1016/j.molimm.2017.08.018 · Cited by 3
Кохан, Е. В., Kiyakbaev, G. K., & Kobalava, Z. D. (2019) · Arterial’naya Gipertenziya (Arterial Hypertension) · doi:10.18705/1607-419x-2019-25-4-389-406 · Cited by 3
Jolicoeur, M. E., & Henry, T. D. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-42880-4.00027-3 · Cited by 3
Lowering Heart Rate Post Revascularization
Giannoglou, G. D., Giannopoulos, A. A., & Chatzizisis, Y. S. (2016) · Angiology · doi:10.1177/0003319716632088 · Cited by 3
Shrivastava, A., Patel, P. C., Tiwari, M., Shanno, K., Soni, S., Sahu, P. K., Goyal, S., Dwivedi, S., Singh, K., & Noman, A. A. (2025) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.70180 · Cited by 2
Spadotto, A., Fusaroli, M., Carelli, M., Nardi, E., Amadori, M., Massaro, G., Angelis, V. D., Gatti, M., Ciubine, V., Raschi, E., et al. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1638923 · Cited by 2
Novel Therapies for the Treatment of Cardiovascular Disease
Asbeutah, A. A., & Goldberger, Z. D. (2024) · Medical Clinics of North America · doi:10.1016/j.mcna.2024.03.003 · Cited by 2
Manolis, A. J., Collins, P. M., Kallistratos, M. S., & Rosano, G. M. C. (2025) · Hellenic Journal of Cardiology · doi:10.1016/j.hjc.2025.02.003 · Cited by 2
HCN Channels and Cardiac Pacemaking
Bucchi, A., Piantoni, C., Barbuti, A., DiFrancesco, D., & Baruscotti, M. (2018) · Cardiac and vascular biology · doi:10.1007/978-3-319-77812-9_5 · Cited by 2
Pharmacological Treatment of Ischemic Heart Disease
Giannoni, A., Gentile, F., & Borrelli, C. (2023) · Springer eBooks · doi:10.1007/978-3-031-25879-4_19 · Cited by 2
Personalized accelerated physiologic pacing
Meyer, M., Infeld, M. M., Habel, N., & Lustgarten, D. L. (2023) · European Heart Journal Supplements · doi:10.1093/eurheartjsupp/suad117 · Cited by 2
Evaluation of the SIGNIFY trial
Grassi, G. M. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1059423 · Cited by 2
Ivabradine in Cardiovascular Disease
Feldman, A. M. (2015) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000237 · Cited by 2
DRUGS EFFICIENCY AND SAFETY: THE ROLE OF PHARMACEUTICAL INDUSTRY
Belyalov, F. I. (2015) · Rational Pharmacotherapy in Cardiology · doi:10.20996/1819-6446-2015-11-4-420-425 · Cited by 2
Perna, G. P., Vagnarelli, F., Volterrani, M., Battistoni, I., & Rapezzi, C. (2016) · Contemporary Clinical Trials Communications · doi:10.1016/j.conctc.2016.06.003 · Cited by 2
Ennezat, P. V., Cosgrove, S., Maréchaux, S., Bouvaist, H., Jemtel, T. H. L., & Durand, D. V. (2017) · Acta cardiologica. Supplementum · doi:10.1080/00015385.2017.1297627 · Cited by 2
Novedades en el tratamiento médico de la cardiopatía isquémica estable
Fácila, L., Urrutia, V. V., & Cabedo, S. M. (2018) · Cardiocore · doi:10.1016/j.carcor.2018.03.004 · Cited by 2
I funny Channel Inhibitors: An Emerging Option for Heart Failure
Kim, Y., Boucher, M., & Argáez, C. (2017) · Europe PMC (PubMed Central) · Cited by 2
Domínguez‐Rodríguez, A. (2015) · Springer eBooks · doi:10.1007/978-3-319-17332-0_7 · Cited by 2
Pharmaka mit Wirkung auf die glatte Muskulatur
Offermanns, S. (2020) · Springer eBooks · doi:10.1007/978-3-662-58304-3_40 · Cited by 2
Kararlı Koroner Arter Hastalığında Güncel İlaç Tedavisi
Tekin, G., & Tekin, A. (2015) · Arşiv Kaynak Tarama Dergisi · doi:10.17827/aktd.91590 · Cited by 3
Medical Management of Chronic Stable Angina
Parker, J. D. (2015) · Springer eBooks · doi:10.1007/978-3-319-15961-4_22 · Cited by 2
The ivabradine journey: Table 1
Ferrari, R. (2015) · European Heart Journal Supplements · doi:10.1093/eurheartj/suv059 · Cited by 2
Self-citationAddressing Major Unmet Needs in Patients with Systolic Heart Failure: The Role of Ivabradine
Pereira-Barretto, A. C. (2016) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-016-0159-2 · Cited by 2
THERAPEUTIC EFFECT ON HEART RATE: VISIBLE SIMPLICITY AND REAL DIFFICULTY
Gilyarevsky, S. R., Golshmid, M. V., & KUZMINA, I. M. (2016) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2016-13-74-80 · Cited by 2
Management of stable coronary artery disease: from evidence to clinical practice
Gerloni, R., Mucci, L., Ciarambino, T., Ventura, M. A. E., Baglio, V., Chiuch, M., Saladini, F., Dorigoni, S., Tizzani, D., & Gnerre, P. (2017) · Italian Journal of Medicine · doi:10.4081/itjm.2017.755 · Cited by 2
Contemporary Management of Patients with Stable Ischemic Heart Disease
Lyubarova, R., Schulman‐Marcus, J., & Boden, W. E. (2019) · Cardiovascular Innovations and Applications · doi:10.15212/cvia.2017.0071 · Cited by 2
Gilyarevskiy, S. R., Golshmid, M. V., & Kuzmina, I. M. (2019) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2019-11-112-121 · Cited by 2
Coronary Heart Disease and Myocardial Ischemia
Groh, S., Dhein, S., & Salameh, A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00081-5 · Cited by 2
Escobar, C., Ariza, A., Barrios, V., Campuzano, R., Freixa‐Pamias, R., Martínez, J. M. G., Olmo, M. R. F., Jorge‐Pérez, P., & Tamargo, J. L. (2022) · Revista Española de Cardiología Suplementos · doi:10.1016/s1131-3587(22)00014-0 · Cited by 2
Potential Relief for Refractory Angina
Granger, C. B., & Gersh, B. J. (2015) · New England Journal of Medicine · doi:10.1056/nejme1413941 · Cited by 2
Pharmacoepidemiology and pharmacovigilance post-marketing drug safety studies
(2024) · Frontiers research topics · doi:10.3389/978-2-8325-5380-0 · Cited by 1
Ivabradine: Evolving role as an antiarrhythmic agent
Janson, C. M. (2025) · Heart Rhythm · doi:10.1016/j.hrthm.2025.06.039 · Cited by 1
Antiarrhythmic drugs to prevent sudden cardiac death: Is there a way forward?
Zieler, I., Curtis, M. J., & Hesketh, L. M. (2026) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2026.109012 · Cited by 1
Lee, J. M., Kim, Y., Lee, S. Y., Kwon, W., Hwang, D., Chon, M. K., Joh, H. S., Lee, S. H., Lee, K. Y., Seo, Y. H., et al. (2026) · Korean Circulation Journal · doi:10.4070/kcj.2026.0191 · Cited by 1
Spinney, L. (2026) · BMJ · doi:10.1136/bmj-2026-100440 · Cited by 1
Translational Cardiology: defining limits and targets at the International Archives of Medicine
Puddu, P. E., & Terracciano, C. M. (2015) · International Archives of Medicine · doi:10.3823/1604 · Cited by 1
Current Role of Ivabradine in Stable Coronary Artery Disease Without Heart Failure
Porres‐Aguilar, M., Muñoz, O. C., & Abbas, A. (2016) · Current Cardiology Reports · doi:10.1007/s11886-015-0689-2 · Cited by 1
Fricke, U., Hein, L., & Schwabe, U. (2016) · Springer eBooks · doi:10.1007/978-3-662-50351-5_3 · Cited by 1
Ivabradina, insufficienza cardiaca e malattia renale cronica
Barbera, G., Santoboni, A., Pascalis, A. D., Rivera, R. F., Floccari, F., Ronco, C., & Lullo, L. D. (2015) · Giornale di Techniche Nefrologiche e Dialitiche · doi:10.5301/gtnd.2015.14772 · Cited by 1
Salem, L., Malouvier, A., Blatchford, J., Rivero‐Ferrer, E., Deltour, N., & Jacquot, E. (2019) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.4880 · Cited by 1
Tomiyama, H., Nakano, H., Takahashi, T., Fujii, M., Shiina, K., Matsumoto, C., Chikamori, T., & Yamashina, A. (2021) · ESC Heart Failure · doi:10.1002/ehf2.13540 · Cited by 1
Gan, H., Tang, H. Y., Huang, Y., Wang, D., Pu, P., & Zuo, Z. (2021) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2203069 · Cited by 1
Riesen, S. C., Bomassi, É., Bracke, A., den Hertog, E., Dukes‐McEwan, J., Eichhorn, G., French, A. T., Höpfner, R., Kirsch, A., Little, C. J. L., et al. (2022) · Journal of Veterinary Cardiology · doi:10.1016/j.jvc.2022.02.007 · Cited by 1
Ivabradina, insufficienza cardiaca e malattia renale cronica
Barbera, G., Santoboni, A., Pascalis, A. D., Rivera, R. F., Floccari, F., Ronco, C., & Lullo, L. D. (2015) · Giornale di Clinica Nefrologica e Dialisi · doi:10.33393/gcnd.2015.808 · Cited by 1
Eschenhagen, T. (2016) · Springer eBooks · doi:10.1007/978-3-662-50351-5_28 · Cited by 1
Terapi Antiangina untuk Angina Pektoris Stabil
Clement, L. (2022) · Cermin Dunia Kedokteran · doi:10.55175/cdk.v49i12.330 · Cited by 1
Zheng, Y., Huang, Q., Fang, X., & Xie, Y. (2024) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.3c01977 · Cited by 1
Eschenhagen, T., & Weil, J. (2025) · Springer eBooks · doi:10.1007/978-3-662-70594-0_7 · Cited by 1
Prevention of non-communicable diseases and special causes of heart failure
Lüscher, T. F. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv303 · Cited by 1
Smetana, G. W. (2016) · Annals of Internal Medicine · doi:10.7326/m15-3104 · Cited by 1
Kaski, J. C. (2016) · Springer eBooks · doi:10.1007/978-3-319-41180-4_3 · Cited by 1
Kaski, J. C. (2016) · Springer eBooks · doi:10.1007/978-3-319-41180-4_6 · Cited by 1
Ivabradine in Takotsubo cardiomyopathy
Said, S. A. (2017) · International Journal of Case Studies in Clinical Research · doi:10.25141/2472-102x-2017-1.0009 · Cited by 1
The role of optimal medical therapy in patients with stable coronary artery disease
Sawhney, J., Kahali, D., Desai, B., Kumar, S., Vishvanathan, M., & Rastogi, V. (2018) · Journal of Clinical and Preventive Cardiology · doi:10.4103/jcpc.jcpc_43_17 · Cited by 1
Clarity and controversy around rate control in AF, the orphan child in AF therapeutics
Aguilar, M., & Nattel, S. (2018) · International Journal of Cardiology · doi:10.1016/j.ijcard.2018.11.024 · Cited by 1
Metabolic Abnormalities and Drugs
Rowan, C. J. (2018) · Oxford University Press eBooks · doi:10.1093/med/9780190225483.003.0023 · Cited by 1
Rasalingam, R., & Boden, W. E. (2019) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2019.01.057 · Cited by 1
Does Ivabradine Decrease Cardiovascular Deaths in Heart Failure Patients?
Marciniak, T. A., Atar, D., & Serebruany, V. L. (2019) · The American Journal of Medicine · doi:10.1016/j.amjmed.2019.07.046 · Cited by 1
Ruiz-Pizarro, V., Vivas, D., Bernardo, E., Ortega, A., Sánchez‐Enrique, C., Enríquez, D., Palacios-Rubio, J., Vilacosta, I., Fernández‐Ortíz, A., & Macaya, C. (2021) · Drugs & Therapy Perspectives · doi:10.1007/s40267-021-00828-z · Cited by 1
Nationale Versorgungsleitlinie (NVL) Chronische KHK
Werdan, K. (2016) · Herz · doi:10.1007/s00059-016-4474-9 · Cited by 1
Katheria, A., Kapoor, A., Sahu, A. K., Raut, K., Khare, H., Khanna, R., Kumar, S., Garg, N., & Tewari, S. (2023) · Indian Heart Journal · doi:10.1016/j.ihj.2023.08.006 · Cited by 1
Can ivabradine reduce NT-proBNP and improve outcomes in systolic heart failure?
Cocco, G., & Jerie, P. (2015) · Cardiology Journal · doi:10.5603/cj.2015.0068 · Cited by 1
Does Ivabradine SIGNIFY Improvements in Quality of Life?
Norris, C. M., & Bainey, K. R. (2016) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.115.002412 · Cited by 1
Ivabradine – well tolerated in elderly patients with systolic heart failure
Zivlas, C., & Foley, P. W. X. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.09.012 · Cited by 1
Özcelik, C. (2014) · Der Kardiologe · doi:10.1007/s12181-014-0630-8
Systolische Herzinsuffizienz bei älteren Patienten
Normann, J. (2015) · Zeitschrift für Gerontologie und Geriatrie · doi:10.1007/s00391-014-0853-0
Stable CAD does not SIGNIFY ivabradine therapy
Lim, G. B. (2014) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2014.149
y, P. A., Bayés‐Genís, A., & de Isla, L. P. (2014) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2014.09.004
Beyond ACE inhibitors and beta-blockers: the use of ivabradine in heart failure
Waterhouse, H. (2015) · British Journal of Cardiac Nursing · doi:10.12968/bjca.2015.10.11.531
Neuartiger Stent im Koronarsinus verbessert Lebensqualität bei therapierefraktärer Angina pectoris
Özcelik, C. (2015) · Der Kardiologe · doi:10.1007/s12181-015-0001-0
Here Comes a Novel Heart-Rate Reducing Therapy in Heart Failure Treatment
Watanabe, T. (2016) · Circulation Journal · doi:10.1253/circj.cj-16-0054
Pinto, F. J. (2015) · European Heart Journal Supplements · doi:10.1093/eurheartj/suv057
Metadata
- Authors
- Fox, K., Ford, I., Steg, P. G., Tardif, J.-C., Tendera, M., & Ferrari, R.
- Affiliations
- Inserm (FR)
- University of Glasgow (GB)
- Montreal Heart Institute (CA)
- University of Ferrara (IT)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-09-18
- Volume
- 371
- Issue
- 12
- Pages
- 1091-1099
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2153622558
- Cited by
- 486
- References
- 19
- Citations by year
- 2026: 10 · 2025: 16 · 2024: 30 · 2023: 34 · 2022: 29 · 2021: 29 · 2020: 27 · 2019: 44 · 2018: 35 · 2017: 49 · 2016: 95 · 2015: 68 · 2014: 18
- FWCI
- 52.69
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, other-oa)
- HAL (submittedVersion)
- Institutional Research Information System University of Ferrara (University of Ferrara) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- National Institute for Health and Care Research (NF-SI-0611-10149)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart rate and cardiovascular health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Rate Variability and Autonomic Control
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Health and Mental Health
- Keywords
- ivabradine, stable coronary artery disease, heart rate reduction, cardiovascular mortality, myocardial infarction, bradycardia, non-inferiority, left ventricular dysfunction, target heart rate, drug safety and efficacy, atrial fibrillation
- MeSH terms
- Ivabradine, Adrenergic beta-Antagonists, Aged, Angiotensin-Converting Enzyme Inhibitors, Benzazepines, Cardiovascular Diseases, Coronary Artery Disease, Double-Blind Method, Drug Therapy, Combination, Female, Heart Failure, Heart Rate, Humans, Male, Middle Aged, Risk, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Kaplan-Meier Estimate, Intention to Treat Analysis, Angina, Stable
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
